Penetration of Vancomycin into the Cerebrospinal Fluid: A Systematic Review

被引:62
作者
Beach, Jessica E. [1 ]
Perrott, Jerrold [1 ,2 ]
Turgeon, Ricky D. [3 ]
Ensom, Mary H. H. [1 ,4 ]
机构
[1] Univ British Columbia, Fac Pharmaceut Sci, 2405 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada
[2] Vancouver Gen Hosp, 899 W 12th Ave, Vancouver, BC V5Z 1M9, Canada
[3] Univ Alberta, Dept Med, Div Cardiol, 2C2 WMC,8440-112 St NW, Edmonton, AB T6G 2B7, Canada
[4] Childrens & Womens Hlth Ctr British Columbia, 4480 Oak St, Vancouver, BC V6H 3N1, Canada
关键词
PNEUMOCOCCAL MENINGITIS; INTRAVENTRICULAR VANCOMYCIN; PHARMACOKINETICS; PHARMACODYNAMICS; INFECTIONS; MANAGEMENT; THERAPY;
D O I
10.1007/s40262-017-0548-y
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Infectious disease and pharmacokinetic textbooks indicate that vancomycin has poor penetration into the central nervous system due to its hydrophilic nature and high molecular weight. Recent literature suggests that penetration of vancomycin into cerebrospinal fluid (CSF) is higher than previously reported; therefore, we conducted a systematic review to assess the penetration of vancomycin into CSF. We searched the MEDLINE, EMBASE, and CENTRAL electronic databases for English-language human studies evaluating serum and CSF concentrations of intravenous vancomycin. In 13 identified studies, the CSF-to-serum ratio of vancomycin varied from 0.00 to 0.81. CSF penetration ranged 0.06-0.81 in patients with meningitis, 0.05-0.17 in ventriculitis, 0.00-0.36 in other infections, and 0-0.13 in patients without infection. Despite variable CSF penetration, 83% of patients with meningitis and 100% of patients with ventriculitis achieved clinical cure. No factor predicted vancomycin CSF penetration. Contrary to prior belief, studies included in our review did not show universally low penetration of vancomycin into CSF. CSF vancomycin levels were variable and did not predict clinical cure.
引用
收藏
页码:1479 / 1490
页数:12
相关论文
共 27 条
[1]  
Agrawal A., 2008, Infect Dis Clin Pract, V16, P100, DOI [10.1097/IPC.0b013e318142ce2c, DOI 10.1097/IPC.0B013E318142CE2C]
[2]   Pharmacodynamics of vancomycin for the treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis [J].
Ahmed, A ;
Jafri, H ;
Lutsar, I ;
McCoig, CC ;
Trujillo, M ;
Wubbel, L ;
Shelton, S ;
McCracken, GH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (04) :876-881
[3]   Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit [J].
Albanèse, J ;
Léone, M ;
Bruguerolle, B ;
Ayem, ML ;
Lacarelle, B ;
Martin, C .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (05) :1356-1358
[4]   Vancomycin Therapeutic Drug Monitoring in Cerebrospinal Fluid [J].
Aouinti, Imen ;
Charfi, Rim ;
Trabelsi, Sameh ;
Gaies, Emna ;
Salouage, Issam ;
Jebabli, Nadia ;
El Jebari, Hanene ;
Lakhal, Mohamed ;
Klouz, Anis .
THERAPIE, 2014, 69 (06) :529-530
[5]   Levels of vancomycin in the cerebral interstitial fluid after severe head injury [J].
Caricato, A ;
Pennisi, M ;
Mancino, A ;
Vigna, G ;
Sandroni, C ;
Arcangeli, A ;
Antonelli, M .
INTENSIVE CARE MEDICINE, 2006, 32 (02) :325-328
[6]  
GERACI JE, 1956, P STAFF M MAYO CLIN, V31, P564
[7]  
Gilbert DN, 2014, SANFORD GUIDE ANTIMI, P86
[8]   Reporting Guidelines for Clinical Pharmacokinetic Studies: The ClinPK Statement [J].
Kanji, Salmaan ;
Hayes, Meghan ;
Ling, Adam ;
Shamseer, Larissa ;
Chant, Clarence ;
Edwards, David J. ;
Edwards, Scott ;
Ensom, Mary H. H. ;
Foster, David R. ;
Hardy, Brian ;
Kiser, Tyree H. ;
la Porte, Charles ;
Roberts, Jason A. ;
Shulman, Rob ;
Walker, Scott ;
Zelenitsky, Sheryl ;
Moher, David .
CLINICAL PHARMACOKINETICS, 2015, 54 (07) :783-795
[9]  
Katzung BG, 2009, BASIC CLIN PHARM, P786
[10]  
Kirby WMM, 1957, ANTIBIOTICS ANN 1956